REXO4

Summary

REXO4 (RNA exonuclease 4, HGNC:12820) is a protein-coding gene on chromosome 9q34.2, encoding RNA exonuclease 4 (Q9GZR2).

Enables DNA binding activity and nuclease activity. Involved in DNA catabolic process and DNA repair. Located in nuclear speck and nucleolus.

Source: NCBI Gene 57109 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 53 total
• MANE Select transcript: NM_020385

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12820
Approved symbol	REXO4
Name	RNA exonuclease 4
Location	9q34.2
Locus type	gene with protein product
Status	Approved
Aliases	hPMC2
Ensembl gene	ENSG00000148300
Ensembl biotype	protein_coding
OMIM	602930
Entrez	57109

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000371935, ENST00000371942, ENST00000445916, ENST00000454825, ENST00000478037, ENST00000494045, ENST00000903990, ENST00000903991, ENST00000903992, ENST00000903993, ENST00000903994

RefSeq mRNA: 4 — MANE Select: NM_020385 NM_001279349, NM_001279350, NM_001279351, NM_020385

CCDS: CCDS65179, CCDS6969

Canonical transcript exons

ENST00000371942 — 8 exons

Exon	Start	End
ENSE00000984212	133410985	133411073
ENSE00000984213	133408768	133408842
ENSE00000984214	133407807	133407881
ENSE00001135646	133417620	133418010
ENSE00003510965	133412778	133412921
ENSE00003532257	133406062	133407072
ENSE00003591439	133414665	133415011
ENSE00003670061	133412299	133412492

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 91.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.2033 / max 156.6170, expressed in 1814 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102997	11.6484	1787
102998	7.6543	1753
102999	0.9007	548

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	91.96	gold quality
skeletal muscle tissue	UBERON:0001134	90.47	gold quality
gastrocnemius	UBERON:0001388	90.09	gold quality
muscle of leg	UBERON:0001383	89.97	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.24	gold quality
mucosa of transverse colon	UBERON:0004991	88.33	gold quality
ventricular zone	UBERON:0003053	88.32	gold quality
muscle tissue	UBERON:0002385	88.00	gold quality
granulocyte	CL:0000094	87.01	gold quality
cortical plate	UBERON:0005343	86.92	gold quality
ganglionic eminence	UBERON:0004023	86.44	gold quality
apex of heart	UBERON:0002098	86.18	gold quality
body of pancreas	UBERON:0001150	85.76	gold quality
placenta	UBERON:0001987	85.48	gold quality
lymph node	UBERON:0000029	85.27	gold quality
prefrontal cortex	UBERON:0000451	85.20	gold quality
lower esophagus mucosa	UBERON:0035834	85.19	gold quality
calcaneal tendon	UBERON:0003701	85.14	gold quality
pancreas	UBERON:0001264	85.05	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.04	gold quality
right lobe of liver	UBERON:0001114	84.93	gold quality
frontal cortex	UBERON:0001870	84.67	gold quality
ovary	UBERON:0000992	84.63	gold quality
left ovary	UBERON:0002119	84.59	gold quality
esophagus mucosa	UBERON:0002469	84.54	gold quality
spleen	UBERON:0002106	84.53	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	84.51	gold quality
stromal cell of endometrium	CL:0002255	84.44	gold quality
heart left ventricle	UBERON:0002084	84.27	gold quality
right frontal lobe	UBERON:0002810	84.10	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.63

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

23 targeting REXO4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-4717-3P	99.06	66.34	1072
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-6834-3P	98.16	65.77	551
HSA-MIR-146B-3P	97.83	65.29	782
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-939-5P	97.10	65.80	1579
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-1343-5P	96.48	66.06	1506
HSA-MIR-3651	95.62	64.67	287
HSA-MIR-4485-3P	93.21	62.11	61

Literature-anchored findings (GeneRIF, showing 1)

• determined that the catalytic activity of hPMC2 is required for repair of abasic sites that result from estrogen-induced DNA damage (PMID:21602889)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rexo4	ENSDARG00000088619
mus_musculus	Rexo4	ENSMUSG00000052406
rattus_norvegicus	Rexo4	ENSRNOG00000027867
drosophila_melanogaster	CG6833	FBGN0036405

Paralogs (5): REXO5 (ENSG00000005189), REXO1 (ENSG00000079313), ISG20L2 (ENSG00000143319), ISG20 (ENSG00000172183), AEN (ENSG00000181026)

Protein

Protein identifiers

RNA exonuclease 4 — Q9GZR2 (reviewed: Q9GZR2)

Alternative names: Exonuclease XPMC2, Prevents mitotic catastrophe 2 protein homolog

All UniProt accessions (3): Q9GZR2, A0A0C4DG22, A0A0C4DG31

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Can bind ESR1 and ESR2. This interaction is abrogated by estrogen and augmented by tamoxifen treatment.

Subcellular location. Nucleus. Nucleolus.

Similarity. Belongs to the REXO4 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9GZR2-1	1	yes
Q9GZR2-2	2

RefSeq proteins (4): NP_001266278, NP_001266279, NP_001266280, NP_065118* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012337	RNaseH-like_sf	Homologous_superfamily
IPR013520	Ribonucl_H	Domain
IPR036397	RNaseH_sf	Homologous_superfamily
IPR037431	REX4_DEDDh_dom	Domain
IPR047021	REXO1/3/4-like	Family

Pfam: PF00929

UniProt features (15 total): compositionally biased region 3, modified residue 3, splice variant 2, sequence variant 2, chain 1, domain 1, sequence conflict 1, region of interest 1, cross-link 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9GZR2-F1	71.20	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 15, 96, 111, 115

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 158 (showing top): GOBP_RIBOSOME_BIOGENESIS, GOMF_ENDONUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_DNA_CATABOLIC_PROCESS, CEBP_Q2, BRN2_01, PETRETTO_HEART_MASS_QTL_CIS_DN, GOBP_DNA_DAMAGE_RESPONSE, LIAO_METASTASIS, GOMF_EXONUCLEASE_ACTIVITY, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, TTCNRGNNNNTTC_HSF_Q6, GOMF_SINGLE_STRANDED_DNA_BINDING

GO Biological Process (6): DNA repair (GO:0006281), DNA catabolic process (GO:0006308), regulation of DNA-templated transcription (GO:0006355), rRNA processing (GO:0006364), RNA processing (GO:0006396), DNA metabolic process (GO:0006259)

GO Molecular Function (10): double-stranded DNA binding (GO:0003690), single-stranded DNA binding (GO:0003697), RNA binding (GO:0003723), endonuclease activity (GO:0004519), exonuclease activity (GO:0004527), 3’-5’ exonuclease activity (GO:0008408), nucleic acid binding (GO:0003676), nuclease activity (GO:0004518), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	2
DNA binding	2
nuclease activity	2
binding	2
nuclear lumen	2
DNA damage response	1
DNA nuclease activity	1
nucleic acid catabolic process	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
RNA processing	1
rRNA metabolic process	1
ribosome biogenesis	1
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
nucleic acid metabolic process	1
nucleic acid binding	1
hydrolase activity, acting on ester bonds	1
exonuclease activity	1
catalytic activity, acting on a nucleic acid	1
catalytic activity	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
intracellular membraneless organelle	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

1988 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
REXO4	REXO2	Q9Y3B8	827
REXO4	CALCOCO2	Q13137	756
REXO4	SP100	P23497	567
REXO4	DEDD	O75618	527
REXO4	CHRAC1	Q9NRG0	463
REXO4	PWP1	Q13610	456
REXO4	SNF8	Q96H20	445
REXO4	KLHL36	Q8N4N3	403
REXO4	SUPT3H	O75486	398
REXO4	PDCD11	Q14690	389
REXO4	ESR1	P03372	380
REXO4	RBM11	P57052	371
REXO4	EBPL	Q9BY08	367
REXO4	HCCS	P53701	367
REXO4	RASGEF1C	Q8N431	362

IntAct

208 interactions, top by confidence:

A	B	Type	Score
H2AX	PPM1G	psi-mi:“MI:0914”(association)	0.730
RPL14	RRP8	psi-mi:“MI:0914”(association)	0.640
H1-1	RRP8	psi-mi:“MI:0914”(association)	0.640
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
RBM34	RRP8	psi-mi:“MI:0914”(association)	0.640
RPL7A	NOP56	psi-mi:“MI:0914”(association)	0.640
NPM1	NVL	psi-mi:“MI:0914”(association)	0.610
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
HSF2BP	REXO4	psi-mi:“MI:0915”(physical association)	0.560
REXO4	DNM2	psi-mi:“MI:0915”(physical association)	0.560
NOS3	REXO4	psi-mi:“MI:0915”(physical association)	0.560
HTT	REXO4	psi-mi:“MI:0915”(physical association)	0.560
ZNF512	ZNF724	psi-mi:“MI:0914”(association)	0.530
RBM34	NVL	psi-mi:“MI:0914”(association)	0.530
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530
H1-4	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
RPL37A	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
ZNF2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
RPL18	NOP56	psi-mi:“MI:0914”(association)	0.530
MACROH2A2	PPM1G	psi-mi:“MI:0914”(association)	0.530
PRR11	NVL	psi-mi:“MI:0914”(association)	0.530
RPL30	RRP8	psi-mi:“MI:0914”(association)	0.530
RPL8	RRP8	psi-mi:“MI:0914”(association)	0.530

BioGRID (332): REXO4 (Affinity Capture-RNA), REXO4 (Affinity Capture-RNA), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Co-fractionation), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS), REXO4 (Affinity Capture-MS)

ESM2 similar proteins: A3BT52, A6NIR3, A6QUM7, B5X564, F4HZF0, F4I114, F4ICB6, F4J394, O49289, P0CQ44, P0CQ45, P34442, Q09719, Q24617, Q38740, Q4IEV5, Q4PER6, Q4WHF8, Q61CX7, Q63553, Q6CE69, Q6CFE7, Q6CMT3, Q6DEW6, Q6P158, Q6P5D3, Q6PAQ4, Q753D9, Q757I9, Q7S9B7, Q8BRB7, Q8HXN7, Q8T3G2, Q8UVR5, Q8VDU5, Q8W1Y3, Q8WML3, Q8WYB5, Q91560, Q92794

Diamond homologs: A1A5R7, A1Z7K9, A3KPE8, A3LRV8, A4RF51, A5DAD0, A5E1W0, B2GUW6, G0SAK8, O94375, O94443, P0C581, P0CQ08, P0CQ09, P0CQ44, P0CQ45, P48778, P53010, P53015, P53331, Q08237, Q09798, Q0CJU7, Q10124, Q2GSV2, Q2T9U5, Q2YDK1, Q3U1G5, Q4PER6, Q4R9F7, Q4WYA1, Q504Q3, Q54U94, Q5AL29, Q5APK0, Q5B367, Q5F450, Q5REE2, Q6AXU3, Q6C462

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 170 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	23	27.8×	1e-25
Viral mRNA Translation	23	27.8×	1e-25
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	23	27.5×	1e-25
Selenocysteine synthesis	23	26.3×	3e-25
Eukaryotic Translation Termination	23	26.3×	3e-25
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	23	25.8×	4e-25
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	23	25.8×	4e-25
Formation of a pool of free 40S subunits	23	24.5×	1e-24

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of DNA recombination	5	36.2×	3e-05
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)	5	30.2×	6e-05
cytoplasmic translation	24	28.7×	7e-26
chromosome condensation	5	27.2×	1e-04
ribosomal small subunit biogenesis	14	20.6×	1e-12
ribosomal large subunit biogenesis	6	17.2×	1e-04
translation	24	15.9×	1e-19
rRNA processing	16	14.6×	3e-12

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1427 predictions. Top by Δscore:

Variant	Effect	Δscore
9:133407805:A:AC	donor_gain	1.0000
9:133407806:C:CA	donor_gain	1.0000
9:133407806:CTGA:C	donor_gain	1.0000
9:133407806:CTGAA:C	donor_gain	1.0000
9:133407878:CACT:C	acceptor_gain	1.0000
9:133407880:CT:C	acceptor_gain	1.0000
9:133407882:C:CC	acceptor_gain	1.0000
9:133408764:GTA:G	donor_loss	1.0000
9:133408765:TA:T	donor_loss	1.0000
9:133408766:A:C	donor_loss	1.0000
9:133408775:TG:T	donor_gain	1.0000
9:133408839:GTAC:G	acceptor_gain	1.0000
9:133408840:TAC:T	acceptor_gain	1.0000
9:133408841:ACCTA:A	acceptor_loss	1.0000
9:133408842:CCTAG:C	acceptor_loss	1.0000
9:133408843:C:CC	acceptor_gain	1.0000
9:133408843:CTAG:C	acceptor_loss	1.0000
9:133410981:GTA:G	donor_loss	1.0000
9:133410982:TACCT:T	donor_loss	1.0000
9:133410984:C:A	donor_loss	1.0000
9:133411069:TTCTC:T	acceptor_gain	1.0000
9:133411071:CTC:C	acceptor_gain	1.0000
9:133411072:TC:T	acceptor_gain	1.0000
9:133411073:CC:C	acceptor_gain	1.0000
9:133411073:CCTG:C	acceptor_loss	1.0000
9:133411074:C:CC	acceptor_gain	1.0000
9:133411075:T:A	acceptor_loss	1.0000
9:133412297:AC:A	donor_gain	1.0000
9:133412298:CC:C	donor_gain	1.0000
9:133412298:CCCTG:C	donor_gain	1.0000

AlphaMissense

2779 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:133412340:C:G	R290T	0.994
9:133412402:G:C	N269K	0.994
9:133412402:G:T	N269K	0.994
9:133408808:C:G	R345P	0.993
9:133411006:G:C	H326Q	0.992
9:133411006:G:T	H326Q	0.992
9:133411010:C:T	G325E	0.992
9:133412339:C:A	R290S	0.992
9:133412339:C:G	R290S	0.992
9:133412340:C:A	R290M	0.992
9:133412413:A:G	S266P	0.992
9:133412418:C:G	R264P	0.992
9:133412421:G:T	A263D	0.992
9:133412468:G:C	D247E	0.992
9:133412468:G:T	D247E	0.992
9:133407019:C:A	W401C	0.991
9:133407019:C:G	W401C	0.991
9:133407065:T:G	D386A	0.991
9:133408806:C:G	D346H	0.991
9:133412327:A:C	S294R	0.991
9:133412327:A:T	S294R	0.991
9:133412329:T:G	S294R	0.991
9:133412370:A:T	V280D	0.991
9:133412475:G:T	A245D	0.991
9:133407021:A:G	W401R	0.990
9:133407021:A:T	W401R	0.990
9:133412412:G:A	S266F	0.990
9:133412462:C:A	E249D	0.990
9:133412462:C:G	E249D	0.990
9:133412463:T:A	E249V	0.990

dbSNP variants (sampled 300 via entrez): RS1000072422 (9:133414106 C>T), RS1000486126 (9:133408399 C>A), RS1000586973 (9:133415624 C>T), RS1000673228 (9:133410743 C>T), RS1000966775 (9:133419270 G>C), RS1001273143 (9:133419030 G>T), RS1001304283 (9:133408934 T>C,G), RS1001439782 (9:133409213 C>T), RS1001620347 (9:133407618 G>A), RS1002298160 (9:133414373 A>T), RS1002318542 (9:133411657 T>C), RS1002330166 (9:133417179 T>A), RS1002468217 (9:133419575 A>G,T), RS1002535539 (9:133415564 G>C), RS1002563267 (9:133419181 T>C)

Disease associations

OMIM: gene MIM:602930 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST004750_24	Squamous cell lung carcinoma	6.000000e-07
GCST010725_19	Malaria	9.000000e-11
GCST010725_31	Malaria	9.000000e-21
GCST010725_98	Malaria	1.000000e-19
GCST012516_2	ABO blood group (AB vs O)	6.000000e-18
GCST012517_2	ABO blood group (B vs O)	4.000000e-22
GCST012518_2	ABO blood group (A vs O)	2.000000e-17
GCST012519_2	ABO blood group (AB vs non-AB)	3.000000e-08
GCST012520_2	ABO blood group (B vs non-B)	8.000000e-09
GCST012522_2	ABO blood group (O vs non-O)	3.000000e-28

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0600062	blood group AB
EFO:0600063	blood group O
EFO:0600061	blood group B
EFO:0600060	blood group A

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	2
Cadmium Chloride	increases abundance, increases expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
bufotalin	increases expression	1
alpha-pinene	increases abundance, affects cotreatment, increases oxidation	1
deoxynivalenol	increases expression	1
terbufos	increases methylation	1
beta-lapachone	increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
coumarin	decreases phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
abrine	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects cotreatment, decreases expression	1
Cytarabine	decreases expression	1
Fonofos	increases methylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Parathion	increases methylation	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2DN	Abcam HeLa REXO4 KO	Cancer cell line	Female
CVCL_TI88	HAP1 REXO4 (-) 1	Cancer cell line	Male
CVCL_XS25	HAP1 REXO4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.